1. Malignant Neoplasms in Russia in 2016 (Morbidity and Mortality). Kaprin AD, Starinskii VV, Petrova GV, eds. Moscow, 2018. Russian.
2. Kiseleva VI, Krikunova LI, Mkrtchan LS, Lyubina LV, Bezyaeva GP, Panarina LV, Saenko AS, Zamulaeva ІA. The significance of physical status of human papillomavirus type 16 for predicting the effectiveness of invasive cervical cancer treatment. Vorp. Onkol. 2013;59(6):756-760. Russian.
3. Rumyantsev PO, Saenko VA, Rumyantseva UV, Chekin SYu. Statistical methods for the analyses in clinical practice. Part 2. Survival analysis and multivariate statistics. Porbl. Endocrinol. 2009;55(6):48-56. Russian.
4. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014;24(2):185-199.
5. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky L.A, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341. c3493. doi: https://doi.org/10.1136/bmj.c3493.